MJFF awards second $2.5M grant to Selonterra for Parkinson’s research

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant of $2.5 million to Selonterra to advance the California-based company’s preclinical development of new therapeutic compounds targeting the genetic causes of Parkinson’s disease. Selonterra specifically will be testing whether compounds that…

MJFF grant supports work into oral therapy to protect nerve cells

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…

MJFF Expands Fellowship Program for Movement Disorder Specialists

To better care for the growing number of people with Parkinson’s disease and their families, the Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program. The two-year fellowship supports medical centers in training a new generation of…

Koneksa Wins MJFF Grant to Investigate Digital Biomarkers

Koneksa has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to investigate the potential of digital biomarkers to evaluate and predict disease progression in people with Parkinson’s disease. Digital biomarkers have the potential to aid in diagnosing Parkinson’s and allowing patients…

Study Planned to Assess Severity of Speech Symptoms

The healthcare technology company Koneksa and Northwestern University plan to begin recruiting patients in the third quarter of this year for a study aimed at measuring the severity of vocal abnormalities that can occur in Parkinson’s disease. The clinical trial, which is expected to be completed in 2024, will…